pirenzepine has been researched along with Chronic Disease in 41 studies
Pirenzepine: An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as CIMETIDINE and RANITIDINE. It is generally well tolerated by patients.
Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).
| Excerpt | Relevance | Reference |
|---|---|---|
| " In this study, pharmacokinetic interactions and clinical effects of adding the CYP1A2 inhibitor fluvoxamine to steady-state olanzapine was examined in patients suffering from schizophrenia." | 9.10 | Fluvoxamine augmentation of olanzapine in chronic schizophrenia: pharmacokinetic interactions and clinical effects. ( Hadjez, J; Härtter, S; Hiemke, C; Jabarin, M; Modai, I; Peled, A; Ritsner, M; Silver, H; Weigmann, H, 2002) |
| "The aim of this study is to provide long-term data on the effectiveness and safety of olanzapine in a group of patients with severe refractory schizophrenia." | 9.10 | Olanzapine for the treatment of chronic refractory schizophrenia: a 12-month follow-up naturalistic study. ( Abel, A; Alvarez, V; Blanco, C; Ciudad, A; Cudeiro, F; Ferreiro, MJ; Gómez, Y; López, A; Peña, C; Prieto, R; Rego, C; Rodríguez-Pérez, V, 2002) |
| "In a 3-month open-label study, 26 clinically stable patients with schizophrenia taking depot antipsychotics for over 3 years were randomly assigned to continue on their current depot dose or to switch to oral olanzapine." | 9.10 | Switching from depot antipsychotic drugs to olanzapine in patients with chronic schizophrenia. ( Godleski, LS; Goldsmith, LJ; Lewis, SJ; Stikovac, DM; Vieweg, WV; Zettwoch, NC, 2003) |
| "This naturalistic study aimed to determine whether olanzapine and clozapine improve cognitive functioning in a sample of 48 patients with chronic schizophrenia who had either failed to show sufficient clinical improvements or suffered from distressing side effects with conventional antipsychotics and were switched to either olanzapine or clozapine for clinical reasons and, if so, whether the two drugs produce similar or different cognitive effects." | 9.10 | Cognitive effects of olanzapine and clozapine treatment in chronic schizophrenia. ( Hughes, C; Kumari, V; Sharma, T; Soni, W, 2003) |
| "The authors compared the efficacy and safety of three atypical antipsychotics (clozapine, olanzapine, and risperidone) with one another and with haloperidol in the treatment of patients with chronic schizophrenia or schizoaffective disorder." | 9.10 | Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. ( Chakos, M; Citrome, L; Cooper, TB; Czobor, P; Lieberman, JA; Lindenmayer, JP; McEvoy, JP; Sheitman, B; Volavka, J, 2002) |
| "This randomized double-blind trial was conducted to test the efficacy and safety of olanzapine in Japanese patients with schizophrenia." | 9.09 | Olanzapine versus haloperidol in the treatment of patients with chronic schizophrenia: results of the Japan multicenter, double-blind olanzapine trial. ( Inada, T; Ishigooka, J; Miura, S, 2001) |
| "The effect of an M1-selective muscarinic receptor antagonist telenzepine on lung function was investigated in 18 patients with chronic obstructive bronchitis in a double blind, placebo-controlled, randomized crossover study." | 9.06 | An M1-selective muscarinic receptor antagonist telenzepine improves lung function in patients with chronic obstructive bronchitis. ( Cazzola, M; D'Amato, G; Guidetti, E; Kilian, U; Staudinger, H; Steinijans, VW, 1990) |
| "Recurrence rates of chronic duodenal ulcer after initial therapy with pirenzepine or cimetidine were investigated in a prospective, randomized trial with a total of 80 patients." | 9.05 | [Recurrence of chronic duodenal ulcer following initial therapy with pirenzepine or cimetidine]. ( Dufek, W; Hentschel, E; Schütze, K, 1985) |
| "The purpose of the present study was to compare the effectiveness of pirenzepine and carbenoxolone in accelerating the healing of chronic gastric ulcer." | 9.05 | Comparison of pirenzepine and carbenoxolone in the treatment of chronic gastric ulcer. A double-blind endoscopic trial. ( Bianchi Porro, G; Daniotti, S; De Pretis, G; Dobrilla, G; Lazzaroni, M; Mazzacca, G; Petrillo, M; Piai, G; Sabbatini, F, 1985) |
| "These data demonstrate that, in older patients with schizophrenia and related psychotic disorders, risperidone and olanzapine have approximately equal efficacy in controlling positive symptoms." | 7.72 | Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years. ( Breier, A; Feldman, PD; Kaiser, CJ; Kennedy, JS; Sutton, VK; Tollefson, GD; Tran, PV; Zhang, F, 2003) |
| "We studied the effect of intravenous pirenzepine (3 mg) in normal subjects (n=15, 43+/-16 years old) and in patients with chronic heart failure (n=15, 61+/-12 years old) to assess the effect of low-dose pirenzepine on vagal activity." | 7.70 | Paradoxical effects of pirenzepine on parasympathetic activity in chronic heart failure and control. ( Furutani, Y; Hayano, T; Ikeda, Y; Matsuzaki, M; Shimizu, A; Ueyama, T; Yamagata, T; Yamamoto, T, 1999) |
| "To date only five reports of neuroleptic malignant syndrome (NMS) related to olanzapine exist." | 7.70 | Neuroleptic malignant syndrome during olanzapine and levomepromazine treatment. ( Järventausta, K; Leinonen, E, 2000) |
| "3 mg telenzepine was well tolerated." | 5.28 | [Pharmacokinetics and tolerability of telenzepine in patients with compensated liver cirrhosis]. ( Dammann, HG; Müller, P; Reinicke, A; Simon, B, 1990) |
| " In this study, pharmacokinetic interactions and clinical effects of adding the CYP1A2 inhibitor fluvoxamine to steady-state olanzapine was examined in patients suffering from schizophrenia." | 5.10 | Fluvoxamine augmentation of olanzapine in chronic schizophrenia: pharmacokinetic interactions and clinical effects. ( Hadjez, J; Härtter, S; Hiemke, C; Jabarin, M; Modai, I; Peled, A; Ritsner, M; Silver, H; Weigmann, H, 2002) |
| "The aim of this study is to provide long-term data on the effectiveness and safety of olanzapine in a group of patients with severe refractory schizophrenia." | 5.10 | Olanzapine for the treatment of chronic refractory schizophrenia: a 12-month follow-up naturalistic study. ( Abel, A; Alvarez, V; Blanco, C; Ciudad, A; Cudeiro, F; Ferreiro, MJ; Gómez, Y; López, A; Peña, C; Prieto, R; Rego, C; Rodríguez-Pérez, V, 2002) |
| "In a 3-month open-label study, 26 clinically stable patients with schizophrenia taking depot antipsychotics for over 3 years were randomly assigned to continue on their current depot dose or to switch to oral olanzapine." | 5.10 | Switching from depot antipsychotic drugs to olanzapine in patients with chronic schizophrenia. ( Godleski, LS; Goldsmith, LJ; Lewis, SJ; Stikovac, DM; Vieweg, WV; Zettwoch, NC, 2003) |
| "This naturalistic study aimed to determine whether olanzapine and clozapine improve cognitive functioning in a sample of 48 patients with chronic schizophrenia who had either failed to show sufficient clinical improvements or suffered from distressing side effects with conventional antipsychotics and were switched to either olanzapine or clozapine for clinical reasons and, if so, whether the two drugs produce similar or different cognitive effects." | 5.10 | Cognitive effects of olanzapine and clozapine treatment in chronic schizophrenia. ( Hughes, C; Kumari, V; Sharma, T; Soni, W, 2003) |
| "The authors compared the efficacy and safety of three atypical antipsychotics (clozapine, olanzapine, and risperidone) with one another and with haloperidol in the treatment of patients with chronic schizophrenia or schizoaffective disorder." | 5.10 | Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. ( Chakos, M; Citrome, L; Cooper, TB; Czobor, P; Lieberman, JA; Lindenmayer, JP; McEvoy, JP; Sheitman, B; Volavka, J, 2002) |
| "This randomized double-blind trial was conducted to test the efficacy and safety of olanzapine in Japanese patients with schizophrenia." | 5.09 | Olanzapine versus haloperidol in the treatment of patients with chronic schizophrenia: results of the Japan multicenter, double-blind olanzapine trial. ( Inada, T; Ishigooka, J; Miura, S, 2001) |
| "The effect of an M1-selective muscarinic receptor antagonist telenzepine on lung function was investigated in 18 patients with chronic obstructive bronchitis in a double blind, placebo-controlled, randomized crossover study." | 5.06 | An M1-selective muscarinic receptor antagonist telenzepine improves lung function in patients with chronic obstructive bronchitis. ( Cazzola, M; D'Amato, G; Guidetti, E; Kilian, U; Staudinger, H; Steinijans, VW, 1990) |
| "Recurrence rates of chronic duodenal ulcer after initial therapy with pirenzepine or cimetidine were investigated in a prospective, randomized trial with a total of 80 patients." | 5.05 | [Recurrence of chronic duodenal ulcer following initial therapy with pirenzepine or cimetidine]. ( Dufek, W; Hentschel, E; Schütze, K, 1985) |
| "The purpose of the present study was to compare the effectiveness of pirenzepine and carbenoxolone in accelerating the healing of chronic gastric ulcer." | 5.05 | Comparison of pirenzepine and carbenoxolone in the treatment of chronic gastric ulcer. A double-blind endoscopic trial. ( Bianchi Porro, G; Daniotti, S; De Pretis, G; Dobrilla, G; Lazzaroni, M; Mazzacca, G; Petrillo, M; Piai, G; Sabbatini, F, 1985) |
| "The unprecedented level of activity in the development of new antipsychotic medications can be traced to the 1989 approval of clozapine by the US Food and Drug Administration for treatment of refractory schizophrenia." | 4.79 | New antipsychotic medications: strategies for evaluation and selected findings. ( Schooler, NR, 1997) |
| "These data demonstrate that, in older patients with schizophrenia and related psychotic disorders, risperidone and olanzapine have approximately equal efficacy in controlling positive symptoms." | 3.72 | Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years. ( Breier, A; Feldman, PD; Kaiser, CJ; Kennedy, JS; Sutton, VK; Tollefson, GD; Tran, PV; Zhang, F, 2003) |
| "By using Israel's National Psychiatric Hospitalization Case Registry, rehospitalization status was monitored for all patients with schizophrenia who were discharged from any inpatient psychiatric facility in Israel while taking risperidone (N=268) or olanzapine (N=313) between Jan." | 3.71 | Rehospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics. ( Davidson, M; Kaplan, Z; Lichtenberg, P; Mark, M; Nahon, D; Rabinowitz, J, 2001) |
| "Clozapine was reserved for more severe forms of schizophrenia, but its cost impact was relatively low." | 3.71 | Service use and costs of treating schizophrenia with atypical antipsychotics. ( Frangou, S; Lewis, M; McCrone, P, 2001) |
| "Glutamate concentrations were measured in serum and were estimated (Glx/Cr) in cingulate cortex by proton magnetic resonance spectroscopy (MRS) in schizophrenia patients while they were being treated with conventional neuroleptics and then 8 weeks after switching to olanzapine." | 3.71 | Modulation of brain and serum glutamatergic concentrations following a switch from conventional neuroleptics to olanzapine. ( Evins, AE; Goff, DC; Hennen, J; Lyoo, IK; Renshaw, PF; Tsai, G; Wald, LL; Yurgelun-Todd, DA, 2002) |
| "We studied the effect of intravenous pirenzepine (3 mg) in normal subjects (n=15, 43+/-16 years old) and in patients with chronic heart failure (n=15, 61+/-12 years old) to assess the effect of low-dose pirenzepine on vagal activity." | 3.70 | Paradoxical effects of pirenzepine on parasympathetic activity in chronic heart failure and control. ( Furutani, Y; Hayano, T; Ikeda, Y; Matsuzaki, M; Shimizu, A; Ueyama, T; Yamagata, T; Yamamoto, T, 1999) |
| "To date only five reports of neuroleptic malignant syndrome (NMS) related to olanzapine exist." | 3.70 | Neuroleptic malignant syndrome during olanzapine and levomepromazine treatment. ( Järventausta, K; Leinonen, E, 2000) |
| "Chronic alcoholic gastritis is a very important social problem in the Health District of Arezzo, which covers an area where wine is an integral part of the diet." | 2.66 | [Alcoholic gastropathy. Notes on its epidemiology and the therapeutic experience using pirenzepine]. ( Agnolucci, A; Angioli, D; Caneschi, F; Cucinelli, ML; Magnolfi, F; Pichi, V; Rossi, G; Valentini, P, 1986) |
| "3 mg telenzepine was well tolerated." | 1.28 | [Pharmacokinetics and tolerability of telenzepine in patients with compensated liver cirrhosis]. ( Dammann, HG; Müller, P; Reinicke, A; Simon, B, 1990) |
| " Plasma concentrations remained in the therapeutic range and the dosage regimen was well tolerated." | 1.28 | Steady-state intravenous pharmacokinetics of pirenzepine in patients with hepatic insufficiency and combined renal- and hepatic insufficiency. ( Bozler, G; Krakamp, B; Leidig, P; Schmitz, R; Tanswell, P; Vogel, H, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (21.95) | 18.7374 |
| 1990's | 8 (19.51) | 18.2507 |
| 2000's | 24 (58.54) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Silberstein, SD | 1 |
| Peres, MF | 1 |
| Hopkins, MM | 1 |
| Shechter, AL | 1 |
| Young, WB | 1 |
| Rozen, TD | 1 |
| Mahendran, R | 1 |
| Hiemke, C | 1 |
| Peled, A | 1 |
| Jabarin, M | 1 |
| Hadjez, J | 1 |
| Weigmann, H | 1 |
| Härtter, S | 1 |
| Modai, I | 1 |
| Ritsner, M | 1 |
| Silver, H | 1 |
| Grieshaber, S | 1 |
| Jatzko, A | 1 |
| Adler, G | 1 |
| Rodríguez-Pérez, V | 1 |
| López, A | 3 |
| Blanco, C | 1 |
| Peña, C | 1 |
| Abel, A | 1 |
| Gómez, Y | 1 |
| Ferreiro, MJ | 1 |
| Rego, C | 1 |
| Cudeiro, F | 1 |
| Alvarez, V | 1 |
| Prieto, R | 1 |
| Ciudad, A | 1 |
| Godleski, LS | 1 |
| Goldsmith, LJ | 1 |
| Vieweg, WV | 1 |
| Zettwoch, NC | 1 |
| Stikovac, DM | 1 |
| Lewis, SJ | 1 |
| Maguire, GA | 1 |
| Phillips, G | 1 |
| Sharma, T | 1 |
| Hughes, C | 1 |
| Soni, W | 1 |
| Kumari, V | 1 |
| Freudenreich, O | 1 |
| Detweiler, MB | 1 |
| Trinkle, DB | 1 |
| Gorski, ED | 1 |
| Willis, KC | 1 |
| Feldman, PD | 1 |
| Kaiser, CJ | 1 |
| Kennedy, JS | 1 |
| Sutton, VK | 1 |
| Tran, PV | 1 |
| Tollefson, GD | 1 |
| Zhang, F | 1 |
| Breier, A | 1 |
| Grigor'ev, PIa | 1 |
| Khar'kovskiĭ, NN | 1 |
| Elina, NA | 1 |
| El'tsova, NB | 1 |
| Elisova, NV | 1 |
| Kalinin, AV | 1 |
| Loginov, AF | 1 |
| Antokhin, EA | 1 |
| Sheitman, BB | 1 |
| Lindgren, JC | 1 |
| Early, J | 1 |
| Sved, M | 1 |
| Schooler, NR | 1 |
| John, V | 1 |
| Rapp, M | 1 |
| Pies, R | 1 |
| Hayano, T | 1 |
| Shimizu, A | 1 |
| Ikeda, Y | 1 |
| Yamamoto, T | 1 |
| Yamagata, T | 1 |
| Ueyama, T | 1 |
| Furutani, Y | 1 |
| Matsuzaki, M | 1 |
| Marcus, EL | 1 |
| Vass, A | 1 |
| Zislin, J | 1 |
| Zänker, S | 1 |
| Khan, M | 1 |
| Farver, D | 1 |
| Järventausta, K | 1 |
| Leinonen, E | 1 |
| Hagger, R | 1 |
| Brown, C | 1 |
| Hurley, P | 1 |
| Rabinowitz, J | 1 |
| Lichtenberg, P | 1 |
| Kaplan, Z | 1 |
| Mark, M | 1 |
| Nahon, D | 1 |
| Davidson, M | 1 |
| Cuesta, MJ | 1 |
| Peralta, V | 1 |
| Zarzuela, A | 1 |
| Ishigooka, J | 1 |
| Inada, T | 1 |
| Miura, S | 1 |
| Smith, RC | 1 |
| Infante, M | 1 |
| Singh, A | 1 |
| Khandat, A | 1 |
| Lewis, M | 1 |
| McCrone, P | 1 |
| Frangou, S | 1 |
| Volavka, J | 1 |
| Czobor, P | 1 |
| Sheitman, B | 1 |
| Lindenmayer, JP | 1 |
| Citrome, L | 1 |
| McEvoy, JP | 1 |
| Cooper, TB | 1 |
| Chakos, M | 1 |
| Lieberman, JA | 1 |
| Goff, DC | 1 |
| Hennen, J | 1 |
| Lyoo, IK | 1 |
| Tsai, G | 1 |
| Wald, LL | 1 |
| Evins, AE | 1 |
| Yurgelun-Todd, DA | 1 |
| Renshaw, PF | 1 |
| Markianos, M | 1 |
| Hatzimanolis, J | 1 |
| Lykouras, L | 1 |
| Christodoulou, GN | 1 |
| Reinicke, A | 1 |
| Müller, P | 1 |
| Dammann, HG | 1 |
| Simon, B | 1 |
| Cazzola, M | 1 |
| D'Amato, G | 1 |
| Guidetti, E | 1 |
| Staudinger, H | 1 |
| Steinijans, VW | 1 |
| Kilian, U | 1 |
| Saakian, Ag | 1 |
| Krakamp, B | 1 |
| Tanswell, P | 1 |
| Leidig, P | 1 |
| Vogel, H | 1 |
| Schmitz, R | 1 |
| Bozler, G | 1 |
| Magnolfi, F | 1 |
| Agnolucci, A | 1 |
| Rossi, G | 1 |
| Caneschi, F | 1 |
| Pichi, V | 1 |
| Cucinelli, ML | 1 |
| Valentini, P | 1 |
| Angioli, D | 1 |
| Guslandi, M | 2 |
| Masci, E | 1 |
| Ballarin, E | 2 |
| Imbimbo, BP | 1 |
| Daniotti, S | 3 |
| Geller, LI | 1 |
| Amatiak, AG | 1 |
| Bessonova, GA | 1 |
| Basilico, M | 1 |
| Tittobello, A | 1 |
| Hentschel, E | 1 |
| Schütze, K | 1 |
| Dufek, W | 1 |
| Bianchi Porro, G | 1 |
| Petrillo, M | 1 |
| Lazzaroni, M | 1 |
| Mazzacca, G | 1 |
| Sabbatini, F | 1 |
| Piai, G | 1 |
| Dobrilla, G | 1 |
| De Pretis, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effects of Glycine Transport Inhibition on Brain Glycine Concentration[NCT00538070] | 68 participants (Actual) | Interventional | 2007-08-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for pirenzepine and Chronic Disease
| Article | Year |
|---|---|
Optimal dosing of medications (in bipolar disorder).
Topics: Acute Disease; Affect; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Ch | 2003 |
New antipsychotic medications: strategies for evaluation and selected findings.
Topics: Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clinical Trials as Topic; Clozapine; Drug Ad | 1997 |
Rapid resolution of antipsychotic-induced tardive dyskinesia with olanzapine.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Chlorpromazine; Chronic Disease; Dysk | 2000 |
Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: a longitudinal study.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Cognition; Female; Humans; Longitudin | 2001 |
14 trials available for pirenzepine and Chronic Disease
| Article | Year |
|---|---|
Fluvoxamine augmentation of olanzapine in chronic schizophrenia: pharmacokinetic interactions and clinical effects.
Topics: Adult; Benzodiazepines; Chemotherapy, Adjuvant; Chronic Disease; Drug Interactions; Female; Fluvoxam | 2002 |
Olanzapine for the treatment of chronic refractory schizophrenia: a 12-month follow-up naturalistic study.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Body Weight; Chronic Disease; Drug Re | 2002 |
Switching from depot antipsychotic drugs to olanzapine in patients with chronic schizophrenia.
Topics: Administration, Oral; Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Chronic Diseas | 2003 |
Cognitive effects of olanzapine and clozapine treatment in chronic schizophrenia.
Topics: Adult; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Cogn | 2003 |
Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: a longitudinal study.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Cognition; Female; Humans; Longitudin | 2001 |
Olanzapine versus haloperidol in the treatment of patients with chronic schizophrenia: results of the Japan multicenter, double-blind olanzapine trial.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Double-Blind | 2001 |
The effects of olanzapine on neurocognitive functioning in medication-refractory schizophrenia.
Topics: Antipsychotic Agents; Benzodiazepines; Chronic Disease; Cognition; Double-Blind Method; Dyskinesia, | 2001 |
Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Double-Blind M | 2002 |
An M1-selective muscarinic receptor antagonist telenzepine improves lung function in patients with chronic obstructive bronchitis.
Topics: Administration, Oral; Adult; Aged; Biometry; Bronchitis; Chronic Disease; Double-Blind Method; Femal | 1990 |
[Alcoholic gastropathy. Notes on its epidemiology and the therapeutic experience using pirenzepine].
Topics: Adult; Aged; Alcoholism; Chronic Disease; Clinical Trials as Topic; Double-Blind Method; Female; Gas | 1986 |
Luminal bicarbonate outflow in chronic antral erosions is suppressed by pirenzepine.
Topics: Adult; Aged; Bicarbonates; Chronic Disease; Double-Blind Method; Female; Gastric Mucosa; Humans; Mal | 1987 |
Pirenzepine in erosive duodenitis. A controlled clinical trial versus ranitidine.
Topics: Adult; Aged; Anti-Ulcer Agents; Benzodiazepinones; Chronic Disease; Clinical Trials as Topic; Double | 1985 |
[Recurrence of chronic duodenal ulcer following initial therapy with pirenzepine or cimetidine].
Topics: Adult; Aged; Benzodiazepinones; Chronic Disease; Cimetidine; Clinical Trials as Topic; Duodenal Ulce | 1985 |
Comparison of pirenzepine and carbenoxolone in the treatment of chronic gastric ulcer. A double-blind endoscopic trial.
Topics: Anti-Ulcer Agents; Benzodiazepinones; Carbenoxolone; Chronic Disease; Clinical Trials as Topic; Doub | 1985 |
24 other studies available for pirenzepine and Chronic Disease
| Article | Year |
|---|---|
Olanzapine in the treatment of refractory migraine and chronic daily headache.
Topics: Antipsychotic Agents; Benzodiazepines; Chronic Disease; Female; Headache Disorders; Humans; Male; Mi | 2002 |
Emergence of compulsive symptoms with olanzapine treatment.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Humans; Male; Obsessive-Compulsive Di | 2002 |
[Mnestic impairment under olanzapine overdosage in an elderly patient].
Topics: Aged; Amnesia; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dose-Response Relationship, D | 2002 |
Treatment noncompliance with orally disintegrating olanzapine tablets.
Topics: Administration, Oral; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Female; Humans; Middle | 2003 |
Fluoxetine augmentation with olanzapine for treatment of chronic resistant depression in an elderly patient: a case report.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Depressive Disorder, Major; Dose-Respo | 2003 |
Report of three case studies with olanzapine for chronic pain.
Topics: Analgesics, Non-Narcotic; Benzodiazepines; Chronic Disease; Female; Humans; Middle Aged; Olanzapine; | 2003 |
Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years.
Topics: Adult; Age Factors; Aged; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Depression; Double | 2003 |
[Treatment of peptic ulcer with gastrozepin].
Topics: Adult; Aged; Anti-Ulcer Agents; Benzodiazepinones; Chronic Disease; Drug Evaluation; Female; Humans; | 1984 |
[The possibilities of using gastrotsepin in treating digestive organ diseases].
Topics: Acute Disease; Adult; Antacids; Anti-Ulcer Agents; Chronic Disease; Digestive System Diseases; Drug | 1993 |
High-dose olanzapine for treatment-refractory schizophrenia.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Chronic Disease; Drug Administ | 1997 |
Aggression, agitation, and mania with olanzapine.
Topics: Adult; Aggression; Akathisia, Drug-Induced; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; | 1998 |
Paradoxical effects of pirenzepine on parasympathetic activity in chronic heart failure and control.
Topics: Adult; Analysis of Variance; Case-Control Studies; Chronic Disease; Echocardiography; Female; Heart | 1999 |
Marked elevation of serum creatine kinase associated with olanzapine therapy.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Creatine Kinase; Humans; Male; Olanza | 1999 |
[Chronic and therapy refractory Fregoli syndrome].
Topics: Antipsychotic Agents; Benzodiazepines; Capgras Syndrome; Chronic Disease; Delusions; Female; Humans; | 2000 |
Neuroleptic malignant syndrome during olanzapine and levomepromazine treatment.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Female; Humans; Methotrimeprazine; Neu | 2000 |
Olanzapine and pancreatitis.
Topics: Adult; Alcohol Drinking; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Humans; Male; Olanz | 2000 |
Rehospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Female; Hospitalization; Humans; Isra | 2001 |
Service use and costs of treating schizophrenia with atypical antipsychotics.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clozapine; Cost-Benefit Analysis; Dos | 2001 |
Modulation of brain and serum glutamatergic concentrations following a switch from conventional neuroleptics to olanzapine.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Creatine; Female; Glutamic Acid; Gyru | 2002 |
Prolactin responses to acute clomipramine and haloperidol of male schizophrenic patients in a drug-free state and after treatment with clozapine or with olanzapine.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Clomipramine; Clozapine; Haloperidol; | 2002 |
[Pharmacokinetics and tolerability of telenzepine in patients with compensated liver cirrhosis].
Topics: Adolescent; Adult; Chronic Disease; Half-Life; Humans; Liver Cirrhosis; Middle Aged; Parasympatholyt | 1990 |
[Effect of gastrozepin on the rate of gastric emptying in patients with peptic ulcer and dumping syndrome following gastric resection].
Topics: Adult; Anti-Ulcer Agents; Atropine; Benzodiazepinones; Chronic Disease; Drug Evaluation; Dumping Syn | 1985 |
Steady-state intravenous pharmacokinetics of pirenzepine in patients with hepatic insufficiency and combined renal- and hepatic insufficiency.
Topics: Adult; Aged; Chronic Disease; Female; Half-Life; Humans; Kidney Diseases; Liver Cirrhosis; Liver Dis | 1989 |
[Gastrozepin and gordox in the treatment of chronic pancreatitis].
Topics: Adult; Aprotinin; Chronic Disease; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Pan | 1986 |